Institutional members access full text with Ovid®

Share this article on:

Radiofrequency ablation for low-grade dysplasia in Barrett's esophagus

Nayna, Lodhia; Emma, Whitcomb; Vani, Konda

Current Opinion in Gastroenterology: July 2016 - Volume 32 - Issue 4 - p 294–301
doi: 10.1097/MOG.0000000000000277
ESOPHAGUS: Edited by Stuart J. Spechler
Editor's Choice

Purpose of review The diagnosis and management of low-grade dysplasia (LGD) in Barrett's esophagus continue to evolve and vary in practice. Radiofrequency ablation (RFA) is now an acceptable option for the treatment of LGD. Therefore, the purpose of this review article is to present current literature on the diagnosis and management of LGD, and to explore when to optimally pursue RFA for the treatment of LGD.

Recent findings The challenge of the management of LGD begins with its diagnosis. Because of high interobserver variability among pathologists in the diagnosis of dysplasia, it is recommended that an expert gastrointestinal pathologist confirms the diagnosis of LGD. Endoscopic mucosal resection is indicated to remove visible lesions in the setting of dysplasia to obtain an accurate diagnosis, especially regarding T staging. Management options include intense surveillance and endoscopic eradication therapy. RFA provides a reasonable method to eradicate flat Barrett's mucosa. Endoscopic eradication of confirmed LGD has been demonstrated to reduce the risk of progression to esophageal cancer. Additional data about the risk factors associated with progression, and the benefits and risks of treatment are discussed, and can be incorporated in patient counseling and decision making.

Summary Endoscopic eradication therapy with RFA may be an appropriate treatment option for LGD in Barrett's esophagus after the benefits and risks have been discussed in detail with the patient.

University of Chicago Medicine, Chicago, Illinois, USA

Correspondence to Vani Konda, MD, University of Chicago Medicine, 5841 S Maryland Ave, MC 4076, Chicago, IL 60637, USA. Tel: +1 773 702 1460; e-mail:

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.